Monopar Therapeutics (MNPR) Projected to Post Quarterly Earnings on Tuesday

Monopar Therapeutics (NASDAQ:MNPR) is expected to issue its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Monopar Therapeutics to announce earnings of ($0.67) per share for the quarter. Investors can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 14, 2026 at 12:30 PM ET.

Monopar Therapeutics (NASDAQ:MNPR) last posted its earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.41. On average, analysts expect Monopar Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Monopar Therapeutics Stock Up 7.0%

NASDAQ MNPR traded up $7.86 on Tuesday, hitting $119.50. The company’s stock had a trading volume of 71,378 shares, compared to its average volume of 220,121. The company’s 50-day moving average is $86.42 and its 200 day moving average is $68.65. The firm has a market cap of $800.65 million, a PE ratio of -62.89 and a beta of 1.47. Monopar Therapeutics has a 1-year low of $29.18 and a 1-year high of $119.05.

Institutional Trading of Monopar Therapeutics

Several hedge funds have recently modified their holdings of MNPR. Invesco Ltd. bought a new position in Monopar Therapeutics during the fourth quarter worth $219,000. ADAR1 Capital Management LLC raised its holdings in shares of Monopar Therapeutics by 79.9% during the fourth quarter. ADAR1 Capital Management LLC now owns 233,908 shares of the company’s stock valued at $15,274,000 after purchasing an additional 103,909 shares during the period. Virtus Investment Advisers LLC acquired a new position in shares of Monopar Therapeutics during the fourth quarter valued at about $233,000. Millennium Management LLC boosted its position in shares of Monopar Therapeutics by 945.5% during the 4th quarter. Millennium Management LLC now owns 76,674 shares of the company’s stock worth $5,007,000 after purchasing an additional 69,340 shares in the last quarter. Finally, Janus Henderson Group PLC grew its stake in shares of Monopar Therapeutics by 2.3% in the 4th quarter. Janus Henderson Group PLC now owns 1,317,410 shares of the company’s stock valued at $85,908,000 after buying an additional 30,042 shares during the period. Institutional investors own 1.83% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on MNPR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Friday, July 17th. Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, July 15th. Zacks Research upgraded Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. HC Wainwright increased their target price on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research report on Wednesday, July 22nd. Finally, BTIG Research raised their price target on shares of Monopar Therapeutics from $104.00 to $117.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Three research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $112.08.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.